NEW YORK – Telix Pharmaceuticals said on Monday that the first glioblastoma patient has received the L-type amino acid transporter 1 (LAT-1)-targeted radiopharmaceutical TLX101 (131I-IPA) with standard-of-care radiation and chemotherapy in a Phase I clinical trial.
To determine patient eligibility for the trial, dubbed IPAX-2, Telix is using its PET imaging agent TLX101-CDx (18F-FET) to identify patients whose cancers overexpress LAT-1. The firm will also use the imaging agent to assess treatment response and cancer progression in patients following treatment with TLX101 plus external beam radiation and temozolomide chemo.
Within IPAX-2, Melbourne, Australia-based Telix is evaluating TLX101's safety and identifying a dose to test in Phase II studies. The company aims to enroll 12 patients in the Phase I trial at six sites in Australia, New Zealand, and Europe.
Telix is launching IPAX-2 after intravenous TLX101 plus external-beam radiation demonstrated safety and preliminary efficacy as a second-line glioblastoma treatment in the IPAX-1 study. Telix is also evaluating TLX101 as a treatment for recurrent glioblastoma in the Phase II IPAX-Linz trial.